Plant Cell Fermentation (PCF®) Technology
Innovator of sustainable solutions to overcome supply constraints for active compounds derived from rare, hard to source, slow-growing or endangered species.
Award-winning, environmentally responsible biotechnology for development of phytochemicals at commercial scale across various industries
Proprietary library of hundreds of plant cell cultures of vascular and non-vascular plants accessible for your development project
Strictly controlled GMP-compliant supply and production processes enable tight product consistency and quality in accordance with regulatory standards
A sustainable solution able to overcome supply constraints for actives derived from rare, hard-to-source, slow-growing or endangered plant species
Scalable, cost-competitive industrial production from kgs to tonnes of annual product volumes
Phyton Biotech offers clients a full range of integrated contract product and process development and commercial manufacturing services across the entire development chain, from feasibility to commercial production.
Latest News
Latest News
Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.
Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).
Latest Events
Latest Case Study
Case Study: Using Green Chemistry to Produce Taxol
Taxol® (manufactured by Bristol-Myers Squibb) is an important drug used to treat many types of solid tumor cancers and Kaposi’s sarcoma. It is on the World Health Organization’s List of Essential Medicines, the most needed medicines in a health care system.